Annual report pursuant to Section 13 and 15(d)

INCOME TAXES (Tables)

v3.22.4
INCOME TAXES (Tables)
12 Months Ended
Dec. 31, 2022
INCOME TAXES  
Schedule of components of the entity's deferred tax assets

As of December 31,

 

    

2022

    

2021

 

Deferred tax assets

Net operating loss carryforwards

$

230,373

$

229,364

Orphan drug and research and development credits

 

68,646

 

66,616

Capitalized research and development credits

15,680

150

Deferred revenue

 

11,234

 

16,297

Deferred compensation

 

9,620

 

8,819

Other, net

 

2,494

 

1,523

Lease liabilities

504

2,564

Deferred tax liabilities

Operating lease right-of-use asset

(461)

(2,335)

Others

(439)

(607)

Total net deferred tax assets

337,651

322,391

Less: valuation allowance

 

(337,651)

 

(322,391)

Deferred tax assets, net of allowance

$

$

Schedule of reconciliation of the statutory federal income tax rate to the effective tax rate

Year Ended December 31,

 

    

2022

    

2021

    

2020

 

Federal statutory tax rate

 

(21.0)

%  

(21.0)

%  

(21.0)

%

State, net of federal benefit

0.0

%  

2.8

%  

0.1

%

Valuation allowance

 

20.2

%  

27.5

%  

24.4

%

Stock compensation

2.5

%  

5.6

%  

4.7

%

Orphan drug and research and development credits

(2.6)

%  

(14.0)

%  

(12.7)

%

Other, net

 

1.0

%  

2.7

%  

4.6

%  

Effective tax rate

 

0.1

%  

3.6

%  

0.1

%  

Schedule of activity related to the entity's gross unrecognized tax benefits

The following table summarizes the activity related to our gross unrecognized tax benefits (in thousands):

Year Ended December 31,

 

    

2022

    

2021

    

2020

 

Balance at the beginning of the year

$

9,186

$

8,901

$

8,358

Increase related to current year tax positions

 

240

 

285

 

543

Balance at the end of the year

$

9,426

$

9,186

$

8,901